Fundraisings and IPOs

Date: 2021-01-07

Type of information: Series A financing round

Company: Lexeo Therapeutics

Investors: Longitude Capital (USA-CA) Omega Funds (USA-MA) Lundbeckfonden Ventures (DK) PBM Capital (USA-VA) Janus Henderson Investors (UK) Invus (USA-NY) Woodline Partners LP (USA-CA) the Alzheimer’s Drug Discovery Foundationi (USA-NY) Alexandria Venture Investments (USA-CA)

Amount: $85 Million

Funding type: series A financing round

Planned used:

Proceeds from the financing will help advance Lexeo’s three lead investigational programs, including: - LX2006, an IV-administered therapy for cardiomyopathy associated with Friedreich’s ataxia (Phase 1 start planned for 2021); - LX1004, a CNS-administered therapy for CLN2 Batten disease (Phase 1/2 completed)
- LX1001, a CNS-administered therapy forAPOE4-associated Alzheimer’s disease (Phase 1 ongoing).

Others: • On January 7, 2021, Lexeo Therapeutics, a clinical-stage gene therapy company, debuted with an oversubscribed $85 million Series A financing, led by Longitude Capital and Omega Funds, and joined by Lundbeckfonden Ventures, PBM Capital, Janus Henderson Investors, Invus, Woodline Partners LP, the Alzheimer’s Drug Discovery Foundationi and Alexandria Venture Investments. Founder and Chief Scientific Advisor Dr. Ronald Crystal is Professor and Chairman of Weill Cornell’s Department of Genetic Medicine and Director of the Belfer Gene Therapy Core Facility. Dr. Crystal has more than 30 years of experience with adenovirus and adeno-associated virus vectors, from basic vector design through clinical development. Dr. Crystal has 14 approved gene therapy investigational new drug applications and has published more than 300 papers on gene therapy, with experience in
CNS, cardiac, pulmonary and liver-mediated diseases.

Lexeo Therapeutics’ Chairman, Dr. Steven Altschuler, is currently Managing Director at Ziff Capital Investments and was formerly Chairman of gene therapy biotech pioneer Spark Therapeutics, which was responsible for the first FDA-approved gene therapy, Luxturna®, and was acquired by Roche in 2019 for $4.3 billion.
Lexeo Therapeutics has also appointed Dr. Jay Barth as Executive Vice President and Chief Medical
Officer to oversee Medical Affairs, Regulatory Affairs and Clinical Development. Dr. Barth Therapeutic area: Rare diseases - Genetic diseases -Neurodegenerative diseases - Cardiovascular diseases

Is general: Yes